Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04609592

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Gastroenteropancreatic Neuroendocrine Tumor Clinical Trial

Official title:
Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery

Clinical Trial Summary

The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use before and after surgery is thought to increase the overall survival benefit for patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.

Clinical Trial Description

Primary Objective(s) - To assess feasibility and safety of combination of perioperative 177Lu Dotatate and cytoreductive surgery in metastatic GEP NETs Secondary Objective(s) - To assess response rate (RR) after 2 cycles 177Lu Dotatate - To assess recurrence free survival (RFS) of the overall treatment strategy - To assess overall survival (OS) of the overall treatment strategy ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04609592
Study type Interventional
Source Stanford University
Contact Gino Pinedo
Phone 650-725-8474
Email gpineda@stanford.edu
Status Recruiting
Phase Phase 1
Start date March 17, 2021
Completion date September 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06155318 - 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Terminated NCT01994213 - A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor Phase 2
Active, not recruiting NCT03980925 - Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Phase 2
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Completed NCT04852679 - Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs Phase 3
Enrolling by invitation NCT05064150 - Neuroendocrine Tumors - Patient Reported Outcomes
Active, not recruiting NCT04727723 - Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
Recruiting NCT06256705 - Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort N/A
Active, not recruiting NCT05477576 - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3
Recruiting NCT05701241 - Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Phase 4
Completed NCT02948946 - Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Withdrawn NCT04915144 - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs Phase 2
Recruiting NCT04986085 - Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Active, not recruiting NCT05262556 - NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas Phase 1
Completed NCT03017690 - Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)